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ABSTRACT: Artiﬁcial antigen-presenting cells (aAPCs) have
recently gained a lot of attention. They eﬃciently activate T
cells and serve as powerful replacements for dendritic cells in
cancer immunotherapy. Focusing on a speciﬁc class of
polymer-based aAPCs, so-called synthetic dendritic cells
(sDCs), we have investigated the importance of multivalent
binding on T-cell activation. Using antibody-functionalized
sDCs, we have tested the inﬂuence of polymer length and
antibody density. Increasing the multivalent character of the
antibody-functionalized polymer lowered the eﬀective concen-
tration required for T-cell activation. This was evidenced for
both early and late stages of activation. The most important
eﬀect observed was the signiﬁcantly prolonged activation of the stimulated T cells, indicating that multivalent sDCs sustain T-cell
signaling. Our results highlight the importance of multivalency for the design of aAPCs and will ultimately allow for better
mimics of natural dendritic cells that can be used as vaccines in cancer treatment.
■ INTRODUCTION
One important goal of cancer immunotherapy is the
replacement of costly dendritic cell (DC) vaccines with
synthetic variants, thereby overcoming the need of generating
a customized vaccine for every individual patient.1 These
synthetic variants, called artiﬁcial antigen-presenting cells
(aAPCs), are designed to prime T cells against cancer-speciﬁc
antigens. These aAPCs can be produced in a straightforward
manner from synthetic building blocks, opening up the
possibility for standardized “oﬀ-the-shelf” protocols2 and
circumventing elaborate and expensive personalized medicine.
Diﬀerent aAPC designs have been synthesized over the last
years with scaﬀolds varying from polymer beads,3,4 carbon
nanotubes,5 liposomes,6 and many others.7 In general, the
design of aAPCs is inspired by the natural DC and its
interaction with the T cell. DC binding to T cells involves three
main signals that are all required to fully activate the T cell:
antigen-loaded major histocompatibility complexes (pMHC) of
the DC bind to speciﬁc T-cell receptors (TCR; signal 1). At the
same time, co-stimulatory molecules on the DC surface interact
with their T-cell binding partners (signal 2). In addition to
these receptor interactions, soluble factors (cytokines) are also
involved in T-cell activation (signal 3). In the ﬁrst stage of
activation, signal 1 interactions trigger the TCR, which is
prearranged in nanoclusters in the T-cell membrane (up to 20
TCRs per cluster).8−12 In the next step, triggered TCR
molecules re-arrange together with signal 2 interactions, to
form larger signaling microclusters containing around 20−300
TCRs.9,11,13−16 These contact areas between both cells are
stabilized by a number of diﬀerent adhesion molecules. After
the initial stimulation, triggered microclusters move toward the
so-called supramolecular adhesion complex where receptors
and adhesion molecules are rearranged to form a “bulls eye”
pattern of micrometer size.17 This process clearly involves the
dynamic multivalent binding of many (diﬀerent) binding
partners.
Multivalent interactions generally form at the interface
between two objects that carry multiple, complementary
functionalities.18,19 The simultaneous interaction between
these functionalities enhances the binding strength (avidity),
sometimes by several orders of magnitude compared to the
aﬃnity of the monovalent interaction.20 This enhancement
mainly originates from an increase in the eﬀective concen-
tration of identical binding partners. Once the ﬁrst ligand is
bound, the “search volume” is reduced, and the following
binding events occur with a higher probability.21 We have
recently introduced a new multivalent aAPC design for
activating T cells: synthetic dendritic cells (sDCs).22,23 In this
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design, anti-CD3 antibodies (αCD3), which are known to
trigger the TCR (signal 1), were bound to a semiﬂexible and
linear polyisocyanopeptide scaﬀold with a length of ∼200 nm.
Using these novel sDCs, T-cell activation occurred at much
lower doses of antibody compared to those of freely soluble
αCD3. This is a direct consequence of the unique physical
properties of the polymer scaﬀold. Its high aspect ratio allows
the eﬃcient simultaneous binding of all αCD3 eﬀector
molecules to the T cell. At the same time, its nanometer size
combined with its semiﬂexibility promotes the dynamic spatial
rearrangement of polymer-bound eﬀector molecules, mimick-
ing the ﬂuidity of the natural cell membrane and supporting
receptor mobility. Coupling of additional anti-CD28 antibodies
(αCD28; signal 2) to the sDC shaped the immunoresponse
toward the induction of helper and killer T cells, without
activating the regulatory T-cell population.23 Remarkably, this
eﬀect was only seen when both signals were bound to one and
the same polyisocyanopeptide backbone, indicating that
activation requires both signals to bind in close spatial
proximity. These results already provided a ﬁrst indication
that multivalent binding of these sDCs does not only increase
the binding strength of the interaction. The polymer
concentrates the eﬀector molecules in a locally conﬁned area.
It may therefore aﬀect T-cell signaling pathways and directly
inﬂuence the strength and speciﬁcity of the T-cell response.
Focusing on sDCs functionalized with only anti-CD3
antibodies (αCD3−sDC), we have now designed a series of
experiments to investigate the eﬀect and importance of
multivalent binding of our sDCs. We have synthesized a
library of αCD3−sDCs with diﬀerent polymer lengths and
αCD3 densities and investigated the inﬂuence of these
parameters on T-cell activation. Incubating T cells with the
αCD3−sDCs, we show that an increase in polymer length and/
or eﬀector molecule density boosts both early (Ca2+-signaling)
and late (interferon γ (IFNγ) release) stages of T-cell activation
and provides evidence that this eﬀect goes beyond a simple
avidity increase. A positive eﬀect on T-cell signaling is further
demonstrated after removal of the αCD3−sDCs. T-cell
activation is sustained for extended periods of time (days), as
conﬁrmed by prolonged Ca2+-signaling, expression of the early
activation marker CD69, and the release of IFNγ.
■ RESULTS AND DISCUSSION
Synthesis of αCD3−sDCs. All polymer−αCD3 conjugates
(i.e., the αCD3−sDCs) were synthesized according to
previously published methods22,23 (Figure 1). The sDC scaﬀold
is based on a water-soluble polyisocyanopeptide co-polymer
bearing nonfunctional methoxy and functional azide groups.
The corresponding methoxy and azide isocyanide monomers
were polymerized using a nickel catalyst to obtain azide-
functionalized polyisocyanopeptide polymers. The azide groups
were subsequently utilized in a strain-promoted azide-alkyne
cycloaddition (SPAAC) reaction with bicyclononyne-function-
alized streptavidin (BCN−SAv).24 The SAv molecules allow for
the binding of biotinylated αCD3 antibodies to yield the
αCD3−sDCs (Figure 1a). In all experiments, the ratio between
SAv and αCD3 was tuned to be 1:1.
Inﬂuence of αCD3−sDC Length on T-Cell Activation.
Polyisocyanopeptides of diﬀerent lengths were synthesized
using diﬀerent catalyst-to-monomer ratios during the polymer-
ization reaction. Two polymers of diﬀerent average lengths
(P1′ = 175 nm and P2′ = 350 nm; azide/methoxy = 1:100)
were synthesized using this strategy (Table S1, Figures S1 and
S2). The density of SAv per polymer chain was determined
using atomic force microscopy (AFM imaging; Table S2,
Figures S1 and S3). The P1−SAv and P2−SAv conjugates
possess an average density of 1 SAv molecule per 110 and 120
nm, respectively. For the synthetic protocol used, we have
shown earlier that one αCD3 antibody is bound per SAv
molecule.22,23 It can therefore be assumed that these values also
represent the densities of αCD3 molecules on the αCD3−sDC
Figure 1. Schematic overview of the sDC library. (a) Experimental design for sDC synthesis. (b) Schematic overview of the sDCs used in this study
(P1−P3) showing the corresponding polymer lengths and αCD3 densities.
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conjugates, P1 and P2 (Figure 1b). This means that P1 carries
1−2 αCD3 molecules per polymer, whereas the total number
of αCD3 molecules on P2 is ∼3.
P1 and P2 were compared with free αCD3 in a single-cell
Ca2+-signaling experiment (Figure 2a). Ca2+-release from the
endoplasmic reticulum is one of the earliest activation events
when triggering T cells at the TCR level. The subsequent
complex interplay between Ca2+-release from the endoplasmic
reticulum and the calcium inﬂux across the plasma membrane
through Ca2+-release-activated Ca2+ (CRAC) channels leads to
oscillations of the cytoplasmic calcium.25 These calcium
oscillations, which have a direct inﬂuence on T-cell gene
expression, were monitored using peripheral blood lympho-
cytes (PBLs) loaded with the Ca2+-sensitive ﬂuorescent dye,
Fura-2 (Table S3, Figure S4, and Movies M1 and M2).26
Determination of the number of Ca2+-signaling cells during the
ﬁrst hour of treatment with P1, P2, or free αCD3 (5 and 25
ng/mL) revealed that the two αCD3−sDCs as well as the free
αCD3 caused a marked increase in the number of Ca2+-
signaling cells (above the 30% background level of Ca2+-
signaling cells observed in the absence of any stimulant27). At
0.5 ng/mL, this eﬀect was only seen for P2 and not for P1 or
free αCD3.
To probe the eﬀect of the two αCD3−sDCs on a late and
more robust event in T-cell activation, we stimulated PBLs for
16 h with P1, P2, and αCD3 and measured the release of IFNγ.
Both αCD3−sDCs stimulated the production of IFNγ over a
range of concentrations from 0.05 to 100 ng/mL (Figure 2b).
At all concentrations tested, the eﬀect of P2 was most
pronounced. Considering that P1 and P2 possess approx-
imately the same αCD3 density, these results suggest that the
polymer length is a crucial design parameter. It increases the
total number of αCD3 molecules per αCD3−sDC, thereby
causing a stronger T-cell-stimulating eﬀect.
Inﬂuence of αCD3 Density on T-Cell Activation. The
previous experiment has shown that a density of one αCD3
antibody in 110−120 nm combined with a polymer length of
maximally 350 nm (P2) leads to a small but clearly detectable
increase in T-cell activation. We therefore decided to increase
both the polymer length and the αCD3 density to investigate
the multivalency eﬀect over a larger dynamic range. On
increasing the number of azide functional groups (azide/
Figure 2. T-cell activation using sDCs of diﬀerent length and αCD3 density. (a) Fraction of activated PBLs as determined from single-cell Ca2+-
signaling measurements performed during the ﬁrst hour of stimulation with P1, P2, and free αCD3. (b) Relative increase in the concentration of
IFNγ secreted by PBLs treated with P1, P2, and free αCD3 for 16 h. Untreated PBLs were used as a reference. (c) Fraction of activated PBLs as
determined from single-cell Ca2+-signaling measurements performed during the ﬁrst hour of stimulation with P3a−c, and free αCD3. (d) Relative
increase in the concentration of IFNγ secreted by PBLs treated with P3a−c, and free αCD3 for 16 h. Untreated PBLs were used as a reference. For
(a)−(c), the data represent the mean ± SEM of three independent experiments performed with T cells from diﬀerent donors. For (d), the data
represent the mean ± SEM of two independent experiments performed with T cells from diﬀerent donors. The number of cells analyzed in the
single-cell Ca2+-signaling experiments (a, c) is summarized in Table S4.
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methoxy = 1:70), polymer P3′ with an average length of 400−
450 nm was synthesized (Table S1, Figures S1 and S2). This
polymer was then functionalized with a diﬀerent number of SAv
molecules per polymer, using diﬀerent ratios of BCN−SAv/
azide in the coupling reaction (0.5, 1, and 5 equiv of BCN−
SAv). Using AFM imaging, the average SAv density on these
polymer conjugates was determined to be 1 SAv molecule in
every ∼130 nm (P3a−SAv, 0.5 equiv), ∼90 nm (P3b−SAv, 1
equiv), and ∼40 nm (P3c−SAv, 5 equiv) (Figure 1b; Table S2,
Figures S1 and S3). Again, it was assumed that these values
correspond to the density of αCD3 antibodies so that the
αCD3−sDCs carry an average of 3−4 (P3a−SAv), 5 (P3b−
SAv), or 10−11 (P3c−SAv) antibodies per polymer.
The single-cell Ca2+-signaling assay shows a marked increase
already at the lowest tested concentration of P3c (0.005 ng/
mL; Figure 2c). In sharp contrast, P3a and P3b displayed the
same dose-dependency as free αCD3. Moreover, for these
αCD3−sDCs, a more clear diﬀerence was observed in the IFNγ
release assay. All three αCD3−sDCs were shown to be more
eﬀective than free αCD3 (Figure 2d). Most importantly, a
positive correlation was observed between αCD3 density and
IFNγ release over the full range of tested concentrations (0.05−
50 ng/mL). At the highest αCD3 concentration of 50 ng/mL,
P3a−c induced a 2.4-, 3.5-, and 6.1-fold increase of secreted
IFNγ, respectively, compared to that by free αCD3. Clearly, in
addition to the polymer length, the αCD3 density is an
important determinant for T-cell activation by αCD3−sDCs.
Quantiﬁcation of the Multivalent Enhancement
Factor. The above results show that both polymer length
and αCD3 density are crucial design parameters for our sDC
design. Together, these parameters determine the number of
interactions that can form between the polymer and the T cell.
To quantify the enhancement of the multivalent binding
strength, dose−response curves were established for both free
αCD3 and the best performing αCD3−sDC (P3c). The dose−
response curves provide the basis for determining the EC50
values and allow for calculating an enhancement factor for the
multivalent interaction. To construct these dose−response
curves, single-cell Ca2+-signaling experiments were performed
over an extended range of αCD3 concentrations (0.001−100
ng/mL). Even though T-cell activation was more diﬃcult to
quantify in the Ca2+-signaling experiment, we have chosen this
readout parameter as it corresponds to a very early activation
event. We believe that an early readout parameter is more
relevant for quantifying the multivalent binding strength than
downstream parameters when signal ampliﬁcation may have
taken place.
When PBLs were treated with P3c, the smallest concen-
tration that caused a detectable eﬀect on the number of Ca2+-
signaling cells was a factor ∼200−300-fold lower than for free
αCD3 (Figure 3), which is in line with previously reported
results.22 For free αCD3, an EC50 value of 16 ng/mL was
found, whereas an EC50 value of 0.24 ng/mL was obtained for
the multivalent P3c. This yields an enhancement factor of ∼67
for the multivalent system (Figure 3).28 This remarkable
enhancement clearly indicates that multivalency is one of the
key parameters responsible for the increased potency of
αCD3−sDCs. It is worth mentioning that the slope of the
dose−response curve usually contains additional information,
for example, about positive or negative cooperativity. The sDC
polymers are heterogeneous, however, when considering both
their length and the αCD3 density. It is therefore highly likely
that the more gradual response to increasing the concentration
of P3c is a direct result of this heterogeneity. We further note
that it would be interesting to increase the αCD3 density on
the polymer to determine whether this multivalent system is
characterized by an optimum loading. Despite several attempts,
we have not been able to attach more αCD3 antibodies to the
polymer, possibly due to steric hindrance.
Assuming that the enhancement factor purely characterizes
the avidity increase of the multivalent interaction, the question
remains whether enhanced binding of the αCD3−sDC is the
only parameter that determines T-cell activation or whether T-
cell signaling is also aﬀected. The polymer linkage between
several αCD3 antibodies eﬃciently directs these polymer-
attached αCD3 antibodies to the same spatially conﬁned area
even if the overall αCD3 concentration is very low. It further
enhances the probability of rebinding after dissociation (koff =
0.39 s−1)29 for individual polymer-attached αCD3 antibodies,
thereby triggering a higher number of TCRs in close proximity.
Considering the sequence of events occurring during T-cell
activation, this may directly lower the threshold concentration
for T-cell activation. A ﬁrst indication for this can be obtained
when re-considering the potency of the αCD3−sDCs P3a−c
(Figure 2c,d) that all bind in a multivalent manner. During all
experiments, the data were normalized to the αCD3
concentration so that the polymer concentration (i.e., the
concentration of T-cell-stimulating entities; αCD3−sDCs)
varies between the diﬀerent samples. When normalizing the
data with respect to the αCD3−sDC concentration, it becomes
evident that a 1000-fold lower concentration of P3c is suﬃcient
to obtain the same eﬀect as with P3a (Figure S5). This value is
considerably larger than the multivalent enhancement factor
determined above and may suggest that the co-localization of a
certain number of αCD3 antibodies in a small area on the cell
surface is a key factor for T-cell activation. Interestingly, a total
number of ∼10 αCD3 antibodies (P3c carries ∼10 antibodies)
distributed over an area of several tens of nanometers matches
with the predicted size of TCR nanoclusters that are preformed
on the T-cell surface.8−10 It may therefore be speculated that
αCD3−sDCs form a highly speciﬁc and dynamic multivalent
interaction with these nanoclusters and that the T-cell fate is
already determined at this very early stage of forming the initial
contact with the T cell.11
Figure 3. Dose−response curves for PBLs treated with P3c and free
αCD3 as determined from single-cell Ca2+-signaling experiments. EC50
values were determined using a four-parameter ﬁt. The multivalent
enhancement factor is calculated by dividing the EC50 of free αCD3 by
the EC50 of P3c. The data represent the mean ± SEM of three
independent experiments performed with PBLs from diﬀerent donors.
The number of cells analyzed is summarized in Table S4.
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Long-Term Eﬀect of αCD3−sDC Binding on T-Cell
Signaling. To investigate the eﬀect of the αCD3−sDCs on T-
cell signaling in more detail, we designed a new series of
experiments to obtain information about sustained T-cell
activation. Instead of measuring T-cell activation in the
continuous presence of the αCD3−sDCs or free antibodies,
excess stimulant was washed oﬀ after 1 h of treatment, and T-
cell activation was analyzed at several time points after removal
of the stimulant. This allowed for determining the long-term
eﬀect of the initial stimulation, as no free stimulant was
available for binding to the T cells after the medium was
replaced. To quantify the eﬀect, we have again performed
single-cell Ca2+-signaling experiments and determined the
secretion of IFNγ. In addition, the expression of the surface
activation marker, CD69, was measured, which is another
indicator of early T-cell activation.
For the single-cell Ca2+-signaling measurements, PBLs were
treated with free αCD3 or P3c (12.5 ng/mL) for 1 h. The
stimulant was then removed, fresh medium was added, and the
cells were incubated without a stimulant for another 15 or 23 h.
Fura-2 was added in the last 20 min of this extended incubation
period, and the fraction of Ca2+-signaling cells was determined
during the following hour (starting at 15 or 23 h after the initial
addition of the stimulant; see Figure S6 for a detailed timeline).
A reference sample was imaged for 1 h in the presence of the
stimulant (0 h; Figure S6). In agreement with the results
presented above (Figures 2c and 3), both free αCD3 and P3c
(12.5 ng/mL) readily increased the number of Ca2+-signaling T
cells during the ﬁrst hour of stimulation (Figure 4a). In samples
treated with free αCD3, the fraction of Ca2+-signaling PBLs was
signiﬁcantly reduced at both poststimulation time points
(Figure S7). In sharp contrast, the vast majority of P3c-treated
PBLs remained active after removal of the stimulant. Even at 24
h after the initial stimulation with P3c, the fraction of Ca2+-
signaling T cells was still ∼75%, indicating that the multivalent
sDC causes a sustained stimulation of the intracellular pathways
involved in Ca2+-responses. Negative controls involving an
isotope control (mIgG2a antibody), polymers with SAv but no
αCD3, and nontreated cells did not show high amounts of
activated T cells before and after removal of the stimulant
(Figure S7).
To support the results from the single-cell Ca2+-signaling
experiments, FACS analysis was performed to determine the
expression of the surface marker CD69. T cells were treated
with P3c or free αCD3 (1, 5, and 50 ng/mL) for 8 h before
placing the PBLs into a fresh medium. At the time of removal
of the stimulant, higher numbers of CD69-expressing T cells
were observed when the PBLs were treated with 50 ng/mL P3c
than when they were treated with the same concentration of
free αCD3 (Figures 4b and S8). On the basis of the multivalent
enhancement factor of 67 (Figure 3), one would expect a
similar level of activation for PBLs treated with 1 ng/mL of P3c
or with 50 ng/mL of free αCD3. When comparing the initial
time point at 8 h, the P3c-treated sample indeed contains
approximately the same number of CD69-expressing cells. This
amount increases during the next 40 h for the P3c-treated
sample, whereas it decreases for the sample treated with free
αCD3.
To further conﬁrm that T cells were showing sustained and
robust activation for an extended period of time, IFNγ release
assays were performed. PBLs were treated with 5 ng/mL P3c
or free αCD3 for 16 h, after which the cells were washed, and a
new medium was added. The supernatant was tested for IFNγ
directly before the removal of the stimulant (16 h), and a high
concentration of IFNγ was determined for both treatment
conditions as expected. At all subsequent time points (24, 48,
72, 96, and 120 h after the initial stimulation), a clear diﬀerence
was seen between T cells treated with P3c or free αCD3
(Figure 4c). PBLs treated with free αCD3 do not seem to
produce new IFNγ, and a decrease in the IFNγ level is seen
Figure 4. Analysis of sustained T-cell activation. (a) Long-term Ca2+-signaling after treating PBLs with 12.5 ng/mL P3c or free αCD3 for 1 h. The
ﬁrst measurement (0 h) was performed directly on the microscope during 1 h of incubation with the stimulant. The other time points represent the
total time of the experiment (i.e., 1 h incubation with the stimulant + incubation time after removal of the stimulant). For all experiments, the data
represent the mean ± SEM of three independent experiments performed with PBLs from diﬀerent donors. The number of cells analyzed is
summarized in Table S5. (b) Fraction of T cells expressing CD69 after treatment with P3c or free αCD3 for 8 h. For P3c, concentrations of 1 and 50
ng/mL are shown. For αCD3, a concentration of 50 ng/mL is shown. The ﬁrst measurement was performed directly before the stimulant was
removed (8 h). The following time points represent the total time of the experiment. For all experiments, the data represent the mean ± SEM of
three independent experiments performed with PBLs from diﬀerent donors. (c) Concentration of secreted IFNγ after treating PBLs with 5 ng/mL
P3c or αCD3 for 16 h. The ﬁrst measurement was performed directly before the stimulant was removed (16 h). The following time points represent
the total time of the experiment. Untreated PBLs were used as a reference. For all experiments, the data represent the mean ± SEM of three
independent experiments performed with PBLs from diﬀerent donors.
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over time. In contrast, PBLs stimulated with P3c produced new
IFNγ. Until the 96 h time point, an approximately constant
level of IFNγ was maintained before a decrease of the IFNγ
concentration was observed. Taken together, these results show
that sDCs stimulate T cells over much longer periods of time
compared with free αCD3, and this eﬀect is observed for both
early and late T-cell activation markers.
Overall, these results show that αCD3−sDCs eﬃciently
activate T cells, combining the beneﬁts of multivalent binding
with a spatially conﬁned interaction with several TCRs. The
equilibrium binding constant of the αCD3 antibody used is KD
= 680 μM29 so that an overall increase in the multivalent
binding strength is seen (enhancement factor of 67). At the
same time, the antibody possesses a relatively fast kinetic oﬀ-
rate, koff = 0.39 s
−1 so that dissociation and immediate
rebinding of individual polymer-attached αCD3 molecules is
highly likely to occur while the sDC is bound to the cell surface.
It has been proposed that such dynamic interactions are
important factors contributing to T-cell activation.30 In addition
to these thermodynamic and kinetic eﬀects, the sDC polymers
keep up to 10 individual eﬀector molecules in close spatial
proximity. It appears likely that one sDC binds within one
nanocluster, and this proximity eﬀect may have direct
consequences for its signaling activity.12 Altogether, these
factors ensure an eﬃcient and long-lasting T-cell activation.
Even though this appears to be the most likely mechanism,
other factors such as altered TCR endocytosis and
exocytosis16,31,32 or changes in membrane properties may
contribute to the observed activation. Investigating these
additional factors will be the subject of further study. Clearly,
our sDC design is a powerful new tool that allows for studying
the initial steps of T-cell activation in more detail, including the
role of TCR nanoclusters. As another important next step, the
αCD3 antibody will be replaced with pMHC complexes.
Natural pMHC complexes bind to the TCR with a slightly
higher KD but similar oﬀ-rates when compared to those of the
αCD3 antibody used.33 The established sDC design principles
can therefore be applied directly for the development of
clinically relevant sDCs.
■ CONCLUSIONS
In summary, we have shown that polymer length and eﬀector
molecule density are key design parameters for the develop-
ment of sDCs. These parameters have a direct eﬀect on the
valency of the sDC and, consequently, on the eﬀective
concentration required for T-cell activation. In addition to
this enhancement of the binding strength, robust and sustained
T-cell activation was observed that goes beyond a pure avidity
eﬀect. Our results show that the multivalent scaﬀold also aﬀects
T-cell signaling pathways. Co-localization of several eﬀector
molecules in the same nano- or micro-cluster leads to a long-
lasting activation that cannot be achieved with nonpolymer-
bound antibodies. Future studies, using natural pMHCs as
eﬀector molecules, will be directed at elucidating the
mechanistic origin of this sustained T-cell response.
■ EXPERIMENTAL SECTION
Polymer Synthesis (P1′−P3′). Water-soluble polyisocya-
nopeptides were synthesized as described using our previously
published method.22 For the synthesis of P1′ and P2′, the
functional azide monomer (N3) and the nonfunctional methoxy
monomer (OMe) were polymerized in a 1:100 ratio. For P3′, a
1:70 N3/OMe ratio was used to increase the number of
possible coupling sites. The polymer length was controlled by
the amount of nickel catalyst added in the polymerization
reaction. A 1:200 ratio of the catalyst/monomer was used for
the synthesis of P1′. For P2′ and P3′, the catalyst/monomer
ratio was 1:10 000. The molecular weight of the polymers was
determined from viscosity measurements (Table S1) as
described previously.22
Synthesis of Polymer−SAv Conjugates. SAv (Thermo
Fisher Scientiﬁc) was functionalized with BCN−POE3-NH-
C(O)CH2CH2CH2C(O)OSu (BCN−NHS; Synaﬃx) to cou-
ple it to the azide-groups on the polymer in a SPAAC
reaction.24 The reaction was performed in borate buﬀer (10
mM, pH 8.5) using a 5−6-fold excess of BCN−NHS. After
incubation for 1.5 hours at room temperature, the mixture was
puriﬁed by ultraﬁltration (10 kDa cutoﬀ) and gel ﬁltration (PD-
10 desalting column; GE Healthcare) to remove nonreacted
BCN−NHS. During puriﬁcation, the buﬀer was exchanged to
phosphate-buﬀered saline (PBS, pH 7.4). Mass spectrometry
analysis (ESI-TOF) revealed that 1−4 BCN moieties were
coupled per SAv molecule (BCN−SAv).
BCN−SAv was subsequently reacted with azide-bearing
polyisocyanopeptide polymers. A 1:1 molar ratio of N3/BCN−
SAv was used for the synthesis of P1−SAv and P2−SAv. N3/
BCN−SAv ratios of 1:0.5, 1:1, and 1:5 were used for the
synthesis of P3a−SAv, P3b−SAv, and P3c−SAv, respectively.
All reactions were performed in PBS. The reaction mixtures
were ﬁrst incubated at room temperature for 1 h and
subsequently stirred at 4 °C for 2.5 days. The resulting
polymer−SAv conjugates were puriﬁed by ultraﬁltration (100
kDa cutoﬀ).
Characterization of Polymer−SAv Conjugates. The
average polymer length and SAv density were determined with
AFM using the method described earlier22 (Figure S1). The
resulting histograms, displaying the distribution of the polymer
length and the SAv distance of at least 41 individual polymers,
are shown in Figures S2 and S3. The results are summarized in
Table S2.
Synthesis of sDCs (P1, P2, and P3a−c). The polymer−
SAv conjugates were incubated with biotinylated, monoclonal
mouse anti-human CD3 antibodies (αCD3; clone OKT3;
puriﬁed in house from the hybridoma cell line) to obtain the
αCD3-functionalized polymers, P1, P2, and P3a−c. The
polymer−SAv conjugates were incubated with the biotinylated
antibodies in a 4:1 αCD3/SAv molar ratio. As previously
described,22 this 4:1 αCD3/SAv molar loading ratio yields a 1:1
binding ratio of αCD3 and SAv on the polymer backbone
(αCD3−sDC).
Cell Preparation and Cell Culture. PBLs were obtained
from buﬀy-coats of healthy individuals in accordance with
institutional guidelines.22 Brieﬂy, peripheral blood mononuclear
cells were obtained from Ficoll density centrifugation.
Monocytes were removed using the plastic ﬂask adherence
method. The nonadherent PBLs were then maintained at 37 °C
and 5% CO2 in complete medium: RPMI-1640 (Lonza),
containing 10% (v/v) fetal bovine serum (Gibco), 1% (w/v)
glutamine (Lonza), and 1× antibiotic−antimycotic (Gibco).
Single-Cell Ca2+-Signaling. The fraction of PBLs respond-
ing to the αCD3−sDC treatment was determined in a single-
cell Ca2+-signaling assay using the ratiometric Ca2+-indicator
Fura-2. PBLs (105 cells) were loaded with 3 μM Fura-2 AM
(Thermo Fisher) in complete medium for 1 h at 37 °C and 5%
CO2. Fura-2-loaded PBLs were washed twice with HEPES
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buﬀered saline (20 mM HEPES pH 7.4, 115 mM NaCl, 5.4
mM KCl, 1 mM CaCl2, 0.8 mM MgCl2, 13.8 mM glucose) and
allowed to adhere to poly-D-L-lysine-coated (0.05 mg/mL;
Sigma-Aldrich) glass-bottom dishes (Nunc) at room temper-
ature. Single-cell Ca2+-measurements were performed as
described before.34 Dishes were placed on the stage of an
inverted microscope (Axiovert 200 M; Zeiss) equipped with a
temperature-controlled CO2 stage incubator (37 °C and 5%
CO2) and a 63×, 1.25 NA objective (Plan NeoFluar). Fura-2
was excited at 340 and 380 nm alternatingly, using a
monochromator (Polychrome IV; TILL Photonics). The
emitted light was directed through a 415 DCLP dichroic
mirror (Omega Optical) and a 510WB40 emission ﬁlter
(Omega) onto a CoolSNAP HQ monochrome CCD camera
(Roper Scientiﬁc). The camera exposure time was 30 ms, and
the time between two ratio images was 2−4 s. All hardware was
controlled with Metaﬂuor 6.0 software (Universal Imaging).
The images obtained were analyzed using Image-Pro Plus
software (Media Cybernetics). Regions of interest (ROIs),
corresponding to individual PBLs, were selected together with a
cell-free ROI for background correction. For each ROI, the
average pixel intensity was calculated for each excitation
wavelength. After subtraction of the corresponding background
value, the 340/380 nm ﬂuorescence emission ratio was
calculated as a measure of the cytosolic Ca2+-concentration.
Increases in cytosolic Ca2+-concentration were identiﬁed with
GraphPad Prism 5 (GraphPad Software), using as criterion that
the increase in the 340 nm signal is mirrored by a decrease in
the 380 nm signal.
To investigate the early eﬀects of diﬀerent αCD3−sDCs on
Ca2+-signaling, a series of experiments was performed. These
experiments include measurements to compare the eﬀect of
diﬀerent αCD3−sDCs (experiments 1 and 2 in Table S3) and
the dose dependences of P3c and freely soluble αCD3
(experiment 3 in Table S3). For these experiments, the dishes
with the Fura-2-loaded T cells were placed onto the
microscope, and imaging was started. The diﬀerent stimulants
were added 5 min after the onset of imaging. After 1 h of
imaging, 1 μg/mL of ionomycin was added to test for cell
viability. The number of cells analyzed for every experimental
condition tested is summarized in Table S4. Typical raw data of
PBLs stimulated with αCD3−sDC or free αCD3 are shown in
Figure S4 and Movies M1 and M2. The movies (60× speed)
show Fura-2-loaded PBLs treated with free αCD3 (Movie M1)
or with the sDC-αCD3 P3c (Movie M2). Each movie shows 5
min of baseline imaging and 1 h of imaging in the presence of
the stimulant. The last 5 min of each movie show the cells in
the presence of ionomycin. The movies were captured with a
frame rate of 0.25 s−1. The data show that PBLs display
diﬀerent patterns of Ca2+-signaling. In this study, we restricted
ourselves to determining the fraction of Ca2+-signaling cells.
To establish the long-term eﬀect of P3c on single-cell Ca2+-
signaling, PBLs were treated with the respective stimulant for 1
h, followed by incubation without the stimulant for an extended
period of time. The following conditions were tested:
untreated, P3c, free αCD3, P3−mIgG2a (isotype control; 40
nm mIgG2a spacing), and P3c−SAv (lacking αCD3). In more
detail, PBLs (105 cells) were incubated with the respective
stimulant (12.5 ng/mL) for 1 h at 37 °C and 5% CO2. At the
end of this stimulation period, the cells were washed with
RPMI-1640 medium lacking the serum and the antibiotics to
remove the stimulant. The cells were resuspended in a fresh
complete medium and maintained at 37 °C and 5% CO2 for
another 15 or 23 h (Figure S6). During the last 20 min of this
poststimulation period, the cells were loaded with Fura-2. The
Fura-2-loaded cells were washed twice with PBS + 1% BSA
(PBA) and imaged under the microscope for 1 h. Cell viability
was assessed at the end of the measurement as described above
(treatment with ionomycin for 5 min). To be able to compare
these poststimulation results with the previously obtained data,
a “0 h” time point was taken at which the PBLs (105 cells) were
ﬁrst loaded with Fura-2 for 20 min and imaged exactly as
described above.
Enzyme-Linked Immunosorbent Assay (ELISA; IFNγ
Secretion). To investigate the eﬀect of the diﬀerent αCD3−
sDCs on IFNγ secretion, PBLs (105 cells/well) were seeded in
96-well plates and treated with P1, P2, and P3a−c or free
antibodies (αCD3) at diﬀerent concentrations (0.05, 0.5, 5, 50,
and 100 ng/mL) for 16 h at 37 °C and 5% CO2. To determine
the eﬀect of the polymer length, the treatment variables were
P1, P2, and free αCD3 along with an untreated control. The
experiment was performed with PBLs from three diﬀerent
donors, each measured in duplicate. P3a−c were used to
investigate the eﬀect of the αCD3 density (again using free
αCD3 and untreated cells as a control). This experiment was
performed with PBLs from two diﬀerent donors (measured in
duplicate). The concentration of the secreted IFNγ was
determined using a sandwich ELISA as described in our earlier
publications.22,23 Brieﬂy, 96-well plates (Nunc Immunomod-
ules) were coated with a mouse anti-human IFNγ antibody
(Thermo Fisher). After incubation at 4 °C overnight, the plates
were washed and blocked with PBS/Tween (0.05%) and PBS +
1% BSA (PBA), respectively. IFNγ standards (Thermo Fisher)
and supernatants (from treated and untreated cells) were added
into the respective wells and incubated for 1 h at room
temperature. After washing 3× with PBA, the concentration of
IFNγ was detected using a biotinylated mouse anti-human
IFNγ antibody (Thermo Fisher) and a SAv−horseradish
peroxidase (HRP) conjugate (Life Technologies). HRP activity
was detected using tetramethyl benzidine (TMB; Sigma-
Aldrich). Absorption at 450 nm was measured using an
iMark Microplate Reader (Bio-Rad).
To measure the long-term eﬀect of the αCD3−sDC
treatment, PBLs (105 cells/well) were seeded in 96-well plates
and treated with the respective stimulant at 5 ng/mL. The cells
were incubated with the stimulant for 16 h at 37 °C and 5%
CO2. After this incubation time, the cells were washed with
RPMI-1640 medium lacking the serum and the antibiotics.
They were then resuspended in a fresh complete medium with
serum to observe the activation state of the cells after the
stimulant was removed. The IFNγ concentration was
determined directly before the medium was removed (16 h)
and at the following time points after the initial stimulation: 24,
48, 72, 96, and 120 h.
Flow Cytometry (CD69 Expression). To measure the
long-term eﬀect of the αCD3−sDC treatment on CD69
expression, PBLs (105 cells/well) were seeded in 96-well plates
and treated with the respective stimulant (1, 5, and 50 ng/mL).
The cells were incubated with the stimulant for 8 h at 37 °C
and 5% CO2. After this incubation time, a sample was taken for
analysis. The remaining cells were washed with RPMI-1640
medium lacking the serum and the antibiotics. They were then
resuspended in a fresh complete medium with serum to observe
the activation state of the cells after the stimulant was removed.
The cell suspensions were collected at the respective time
points (24, 48, 72, 96, and 120 h after the initial stimulation)
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and used for ﬂow cytometric analysis (CyAn ADP; Beckman
Coulter) following the same methodology as described in our
previous publications.22,23
Brieﬂy, PBLs (treated or untreated) were washed twice with
PBA to remove unbound sDCs or antibodies. PBLs were
stained with antibodies speciﬁc for the CD4/8+ T-cell
subpopulations (APC-labeled mouse anti-human CD4/8
mAb; T-cell marker; BD Pharmingen) and with PE-labeled
mouse anti-human CD69 (eBioSciences). After 1 h of
incubation, the cells were again washed twice with PBA before
performing ﬂow cytometric analysis. The data obtained were
analyzed using FlowJo ver. 9.2 Software (TreeStar Inc.). The
gating strategy is shown in Figure S9.
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(9) Schamel, W. W. A.; Alarcoń, B. Organization of the resting TCR
in nanoscale oligomers. Immunol. Rev. 2013, 251, 13−20.
(10) Dinic, J.; Riehl, A.; Adler, J.; Parmryd, I. The T cell receptor
resides in ordered plasma membrane nanodomains that aggregate
upon patching of the receptor. Sci. Rep. 2015, 5, No. 10082.
(11) Nika, K.; Acuto, O. Membrane nanodomains in T-cell antigen
receptor signalling. Essays Biochem. 2015, 57, 165−175.
(12) Pageon, S. V.; Tabarin, T.; Yamamoto, Y.; Ma, Y.; Nicovich, P.
R.; Bridgeman, J. S.; Cohnen, A.; Benzing, C.; Gao, Y.; Crowther, M.
D.; Tungatt, K.; Dolton, G.; Sewell, A. K.; Price, D. A.; Acuto, O.;
Parton, R. G.; Gooding, J. J.; Rossy, J.; Rossjohn, J.; Gaus, K.
Functional role of T-cell receptor nanoclusters in signal initiation and
antigen discrimination. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, E5454−
E5463.
(13) Varma, R.; Campi, G.; Yokosuka, T.; Saito, T.; Dustin, M. L. T
cell receptor-proximal signals are sustained in peripheral microclusters
and terminated in the central supramolecular activation cluster.
Immunity 2006, 25, 117−127.
(14) Yokosuka, T.; Saito, T. Dynamic regulation of T-cell
costimulation through TCR−CD28 microclusters. Immunol. Rev.
2009, 229, 27−40.
(15) Choudhuri, K.; Dustin, M. L. Signaling microdomains in T cells.
FEBS Lett. 2010, 584, 4823−4831.
(16) Hashimoto-Tane, A.; Saito, T. Dynamic Regulation of TCR−
Microclusters and the Microsynapse for T Cell Activation. Front.
Immunol. 2016, 7, No. 255.
(17) Fooksman, D. R.; Vardhana, S.; Vasiliver-Shamis, G.; Liese, J.;
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